Possible role of pirenzepine on the release of pancreatic polypeptide in duodenal ulcer patients: preliminary results of a randomized cross-over study.
The effects of repeated oral doses of pirenzepine (100 mg daily for 7 days) and antacid (Maalox, 105 ml daily for 7 days) on the test-meal-stimulated release of pancreatic polypeptide (PP) were evaluated in 7 duodenal ulcer outpatients by means of a randomized cross-over study, with a wash-out period of one week between pirenzepine and antacid administration. The effects of pirenzepine (100 mg daily for 7 days) were also evaluated in 5 healthy adult volunteers. The stimulus test was performed on each fasting patient two days before the treatment started and after a 7-day treatment. Venous blood samples were obtained before the test meal (basal) and 3, 10 and 30 minutes after it. Plasma PP levels were estimated by means of a specific RIA. The results obtained showed that pirenzepine significantly inhibits the PP response to the test meal in the duodenal ulcer patients and in the healthy volunteers. The above-mentioned effects suggest that one of the mechanisms of action on the therapeutic activity of pirenzepine on peptic ulcer might be explained by the preservation of pancreatic secretion unimpaired by an increase in PP release after meal stimulus.
D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001570:Benzodiazepinones / Q000494:pharmacology*; D004381:Duodenal Ulcer / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010191:Pancreatic Polypeptide / Q000378:metabolism*; D010890:Pirenzepine; D011897:Random Allocation
D000897:Anti-Ulcer Agents; D001570:Benzodiazepinones; D010890:Pirenzepine; D010191:Pancreatic Polypeptide